Testing LY4005130 for non-segmental vitiligo
Part of Skin clinical trials.
This study tests a new medicine called LY4005130 for non-segmental vitiligo, a skin condition where patches lose pigment (color). The trial aims to see if this drug can help restore skin color and stop the spread of white patches.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have non-segmental vitiligo (the type where white patches can appear anywhere on the body) diagnosed at least 3 months ago
- White patches cover 4–60% of your body surface, but not including palms, soles, or top of feet
- You have at least some involvement on your face (at least 0.5% coverage)
- Your vitiligo is either actively spreading or has stabilized (not getting worse and not improving dramatically)
- You have never taken a JAK inhibitor medicine (such as ruxolitinib, tofacitinib, or baricitinib) before, either as a cream or pill
- You do not have serious heart, lung, liver, stomach, or mental health conditions that could make the study unsafe
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a new tablet called LW402 can help restore skin color in people with non-segmental vitiligo (white patches that spread unpredictably across the body). The medication works by targeting immune cells that attack skin pigment.
This Phase 2 trial tests whether a new drug called D-2570 can help restore skin color in people with non-segmental vitiligo (when white patches appear randomly across the body). The study will track how well the drug works and check if it's safe to use.
This study tests a new medicine called FB102 for people with non-segmental vitiligo. It aims to see if the drug is safe and helps restore skin color.
This trial tests a new cream for vitiligo on the face or neck. It aims to see if the cream can help bring color back to white patches.
This trial tests an ointment called MH004 to see if it helps repigment white patches in people with non-segmental vitiligo (the most common type). It focuses on patches on the face and body.
This trial tests a new gel made from stem-cell substances (secretome) given with narrow-band UVB light therapy for stable non-segmental vitiligo. It compares two ways of applying the gel to see which works better.
Hear when a new Vitiligo trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.